Daily Stock List
Black Ridge Oil & Gas, Inc. (ANFC)
Wall Street Resources reported today on Black Ridge Oil & Gas, Inc. (ANFC), and we are reporting on the Company as well, here at the QualityStocks Daily Newsletter.
Black Ridge Oil & Gas, Inc. is an oil and gas exploration and production company that lists on the OTC Bulletin Board. The Company's focus is exclusive to the Williston Basin Bakken and Three Forks trend in North Dakota and Montana. Black Ridge Oil & Gas controls approximately 12,000 net Bakken and/or Three Forks acres. Founded in 2010, the Company has their headquarters in Minnetonka, Minnesota. The Company formerly went by the name Ante5, Inc. They changed their corporate name to Black Ridge Oil & Gas, Inc. in April of 2012.
Black Ridge Oil & Gas is aggressively increasing their acreage position. The Company is one of the premier non-operating participants in the Bakken and Three Forks play. Since 2010, Black Ridge participates in more than 63 Bakken or Three Forks wells in North Dakota. Being a non-operator, the Company participates in Bakken and Three Forks wells on a proportionate basis. This is according to their leasehold interest in each drilling unit that undergoes drilling by their operating partners.
Black Ridge Oil & Gas takes a minority rather than majority interest in their wells. This strategy generates for the Company a highly diversified portfolio of Bakken and Three Forks wells across the Williston Basin. The benefit of a diversified mineral interest portfolio is lower operational risk on a well-by-well basis. An additional benefit of the non-operator model is that it allows Black Ridge to partner with some of the most experienced and efficient operators in North Dakota.
Furthermore, Black Ridge does not bear the operating and overhead costs of their operating partners. This makes the Company a low-cost producer in the Bakken and Three Forks play.
The Company is pursuing a host of goals. These include acquiring high-potential mineral leases; accessing appropriate capital markets to fund continued acreage acquisition and drilling activities, and developing and maintaining strategic industry relationships. Their goals also include attracting and retaining talented associates; operating the aforementioned low overhead non-operator business model, as well as becoming a low cost producer of hydrocarbons.
Black Ridge Oil & Gas, Inc. (ANFC), closed Friday's trading session at $0.63, up 1.29%, on 7,280 volume with 7 trades. The average volume for the last 60 days is 19,367 and the stock's 52-week low/high is $0.26/$0.80.
IZEA, Inc. (IZEA)
Red Chip reported this week on IZEA, Inc. (IZEA), Stock Exploder, OTC Showcase, Bullish Bankers, HEROSTOCKS, VIP STOCK ALERTS, Liquid Pennies, Stockhunter.us, Stock Edge, PennyStockProfessor, Perfect Penny Stocks did earlier, and we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Listed on the OTC Markets' OTCQB, IZEA, Inc. is the pioneer of social media sponsorship. The Company operates multiple online marketplaces. These include Staree, Sponsored Tweets, as well as SocialSpark. IZEA connects advertisers with social media influencers, helping them monetize their social media presence. IZEA became publicly traded following their acquisition by IZEA Holdings, Inc., a publicly traded Nevada corporation, on May 12, 2011. IZEA has their corporate headquarters in Orlando, Florida.
IZEA believes that the current state of social media sponsorship (SMS) represents a major corporate opportunity for the Company. They address these common problems with targeted, scalable marketplaces that aggregate social media publishers and advertisers. IZEA offers an efficient, innovative way for publishers and advertisers of all sizes to find each other and complete a sponsorship transaction.
IZEA created the social media sponsorship space in 2006. The Company builds strong technology platforms. These platforms connect brands with social media influencers. These range from college students to A-List celebrities. IZEA's network has more than 750,000-plus registered influencers and thousands of brand partners from small business to Fortune 100 corporations.
The Company's owned and operated platforms include the aforementioned Sponsored Tweets, SocialSpark, Staree, plus Featured Users, FanAds, Pinable Ads and IZEA Media. IZEA has completed more than 3 million social media sponsorships across all of their platforms.
Today, IZEA closed on a new $1.5 million secured credit facility with Bridge Bank, N.A. of San Jose, California. The basis of the credit facility is on an advance rate of IZEA's eligible trade accounts receivable.
Mr. Ted Murphy, Founder & Chief Executive Officer of IZEA, said, "The company is delighted to be working with a full-service professional business bank dedicated to meeting the financial needs of emerging technology businesses. Our engagement with Bridge Bank provides us with additional financial flexibility as we continue to grow IZEA."
IZEA, Inc. (IZEA), closed Friday's trading session at $0.25, down 9.09%, on 107,283 volume with 35 trades. The average volume for the last 60 days is 85,200 and the stock's 52-week low/high is $0.13/$28.00.
SoupMan, Inc. (SOUP)
FeedBlitz, Street Beat, and Pumps and Dumps reported previously on SoupMan, Inc. (SOUP), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.
Headquartered in Staten Island, New York, SoupMan, Inc. is a manufacturer and multi-channel marketer of premium soups. They offer these to consumers and the food service industry under the "Original SoupMan" brand. The Company formerly went by the name The Original SoupMan, Inc. They changed their corporate name to SoupMan, Inc. in December of 2010. The Company's shares trade on the OTC Markets' OTCQB.
Their license from Al Yeganeh, the legendary "SoupMan," provides the Company with access to Mr. Yeganeh's recipes, name, likeness, and other intellectual properties. Mr. Yeganeh opened his famous soup shop in 1984 at 55th Street & 8th Avenue in Manhattan. His shop soon became a worldwide destination. The shop gained worldwide fame as the inspiration for the TV show Seinfeld's soup episode. SoupMan owns and operates Al's Original world famous restaurant.
SoupMan's intention is to become the leading national brand of premium soup by focusing on their supermarket distribution channel and their franchised restaurants. The Company also has their ecommerce website. The Company's line consists of numerous varieties of Mr. Yeganeh's original recipes. They are all available to their franchise owners in bulk.
There are five varieties of Al's legendary soup that customers can order from their website. However, 47 soups are available on any given day at any one of the Company's restaurants. All of SoupMan's soups are slow-cooked in small batches using Mr. Yeganeh's original recipes. The Original SoupMan soups are packaged in an innovative, shelf-stable Tetra Recart carton package. This package maintains the taste and quality standards that made The Original SoupMan famous.
SoupMan has franchised and licensed restaurants in heavy traffic locations, such as shopping malls, casinos, airports, and other travel destinations consisting of the Mohegan Sun Casino in Connecticut.
In early January of this year, SoupMan announced that Nash-Finch is now featuring The Original SoupMan among their portfolio of brands.
Nash-Finch, based in Minneapolis, Minnesota, is the second largest publicly traded wholesale food distributor in the U.S. They service thousands of food retailers. Nash-Finch is a Fortune 500 company.
SoupMan, Inc. (SOUP), closed at $0.47, up 6.82%, on 21,519 volume with 8 trades. The average volume for the last 60 days is 10,275 and the stock's 52-week low/high is $0.38/$1.00.
Strike Minerals, Inc. (STK.V)
Today we are reporting on Strike Minerals, Inc. (STK.V), here at the QualityStocks Daily Newsletter.
Strike Minerals, Inc. engages in the exploration and development of precious metal properties in Canada. The Company's primary property is the former producing Edwards Gold Mine property in the Goudreau - Lochalsh Gold Camp near Wawa, Ontario. Established on May 21, 1987, Strike Minerals' focus is gold. The Company has their headquarters in Toronto, Ontario; their shares trade on the TSX Venture Exchange.
The estimation is that historic production in the Goudreau - Lochalsh Gold Camp between 1930 and 2001 is 500,000 ounces. Between 1996 and 2001 underground development was completed through a decline to a depth of approximately 290 m. Mining over the period resulted in 145,000 oz being produced from the Edwards property at an average grade of 0.39 opt. Subsequent drilling on the Edwards Gold Mine property has delineated an additional five zones that have major gold mineralization.
Currently, the Company has dewatered the underground workings below the 140m level. Strike has now completed underground drifting on the 60m and 90m level. The Company is drifting on the Edwards #1 and #5 zones with the plan to be in production this year.
Strike Minerals also has their Hemlo West Properties. The Hemlo West Properties include 35 square kilometers of staked and patented mining claims near Hemlo West, Ontario, approximately 70 km west of the Hemlo gold deposit in the Hemlo West-Hemlo greenstone belt. Furthermore, they Company has their Ronda Properties (100 percent owned by Strike Minerals). The Ronda Properties consist of twelve claims (17 units) that straddle the north-south boundary between Churchill and MacMurchy Townships near Shiningtree, Ontario.
Yesterday, Strike Minerals issued an update at the Edwards Mine Project. They are still planning the underground development plan on the Edwards #1 and #5 delineated gold mineralized zones on the 60m level of their Edwards Mine, 50 km NE of Wawa, Ontario. The dewatering is now at 140m; underground development work continues to extend existing workings on the 60m level and 90m level.
The drifting is planned to cut several mineralized zones where historical diamond drill holes have indicated high-grade gold values between surface and the 100-meter level. So far, development mining on the veins has produced and placed on surface approximately 1,100 tonnes of material with an average grade of 12.83 gpt from the Edwards #1 vein and 2,000 tonnes grading 2.0 gpt from other underground development.
Strike Minerals, Inc. (STK.V), closed Friday's trading session at $0.035, even for the day, on 74,029 volume. The stock's 52-week low/high is $0.03/$0.15.
22nd Century Group, Inc. (XXII)
Ceocast News and Proactivecrg reported previously on 22nd Century Group, Inc. (XXII), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Trading on the OTC Bulletin Board, 22nd Century Group, Inc. focuses on tobacco breeding for new, relevant, and differentiated tobacco products. Based in Clarence, New York, the Company is a plant biotechnology enterprise whose proprietary technology allows for the level of nicotine (and other nicotinic alkaloids) in the tobacco plant to be decreased or increased through genetic engineering and breeding.
Mr. Joseph Pandolfino founded 22nd Century Ltd., LLC (22nd Century) in 1998 to provide funding to North Carolina State University (NCSU) for a research and development collaboration on nicotine biosynthesis in the tobacco plant. Mr. Pandolfino questioned that coffee without caffeine and beer without alcohol are commercially available so why isn't tobacco cigarettes without nicotine a choice for consumers.
22nd Century's commitment is to developing and commercializing consumer-acceptable reduced risk tobacco products and a prescription-based smoking cessation aid consisting of a kit of very low nicotine (VLN) cigarettes. One of their tobacco varieties has 95 percent less nicotine than the tobacco found in typical "light" cigarettes.
22nd Century Group owns or exclusively controls 107 issued patents in 78 countries. The Company additionally has 38 pending worldwide patent applications. In the United States, they own exclusive rights to 14 issued patents and 7 patent applications. In China, they own exclusive rights to 5 issued patents and 3 patent applications.
The Company's proprietary technology allows them to regulate (decrease or increase) the biosynthesis of nicotinic alkaloids in plants via genetic engineering (Kajikawa et al. 2011; Todd et al. 2010). This enables them to regulate nicotine content in tobacco plants without adversely affecting other leaf compounds important to a tobacco product's characteristics. This includes aroma as well as taste. Their technology also enables them to regulate the production of other nicotinic alkaloids in tobacco plants to produce tobacco with a broad spectrum of specific desired alkaloid contents and alkaloid profiles (proportions of individual nicotinic alkaloids).
Goodrich Tobacco and Hercules Pharmaceuticals, LLC are wholly owned subsidiaries of 22nd Century. Goodrich Tobacco focuses on commercial tobacco products and potential modified risk cigarettes. Hercules focuses on X-22, a prescription smoking cessation aid in development.
At the end of January 2013, 22nd Century Group announced that their subsidiary, Goodrich Tobacco applied to the Alcohol and Tobacco Tax Trade Bureau of the United States Treasury Department (TTB) for a federal permit to manufacture their own tobacco products. Until now, Goodrich Tobacco has contracted with independent federally licensed tobacco manufacturers to produce their proprietary commercial products, RED SUN®, MAGIC® and SPECTRUM®.
22nd Century Group, Inc. (XXII), closed Friday's trading at $0.90, up 16.88%, on 214,610 volume with 56 trades. The average volume for the last 60 days is 47,355 and the stock's 52-week low/high is $0.15/$1.13.
Unigene Laboratories, Inc. (UGNE)
StreetInsider, SmarTrend Newsletters, and SmallCapVoice reported earlier on Unigene Laboratories, Inc. (UGNE), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.
Founded in 1980, Unigene Laboratories, Inc. is a leader in the design, delivery, manufacture and development of peptide-based therapeutics. The Company is building a strong portfolio of proprietary partnerships in this expanding drug class based on their Peptelligence™ platform. Unigene is exclusively focused on peptide therapeutics. Peptides are a fast growing therapeutic class. Unigene Laboratories is based in Boonton, New Jersey.
The Company is focusing their Unigene Therapeutics pipeline on metabolic with significant unmet medical and socioeconomic needs. Unigene Therapeutics constitutes the Company's own pipeline of proprietary peptide development programs focusing on metabolic disease and inflammation.
In addition, their intention is to focus their Unigene Biotechnologies business unit on generating near-term fee-for-service revenues and longer-term milestone payments and royalties through customizing delivery and manufacturing solutions for novel therapeutic peptides.
Unigene Laboratories' Peptelligence™ encompasses extensive intellectual property covering drug delivery and manufacturing technologies, research and development expertise, and proprietary expertise. Core Peptelligence™ assets include proprietary oral and nasal peptide drug delivery technologies, and proprietary, high-yield, scalable and reproducible E. coli-based manufacturing technologies.
Unigene has their Oral Peptide Delivery Platform. It is clinically advanced - Positive Phase 3 Oral Calcitonin; Positive Phase 2 Oral Parathyroid Hormon.
This week, Unigene Laboratories commented on the Food & Drug Administration (FDA) Advisory Committee review of Salmon Calcitonin. Ashleigh Palmer, the Company's CEO, stated, "It is our understanding that the FDA will now take the Advisory Committee's recommendations under consideration. Restricting the use of calcitonin drugs has been a possibility since last year's negative EMA ruling on calcitonin containing products. Currently, we are evaluating how the specific recommendations from yesterday's Advisory Committee Meeting are likely to affect Unigene. However, to be clear, they are certain to have a materially adverse impact on the Company's financial situation and operations in the near term. We anticipate being able to provide more details in our upcoming 2012 fourth quarter and year-end update, when we will also discuss other Unigene initiatives and programs not affected by this development."
The Advisory Committee concluded that the benefits of calcitonin products, including Fortical®, do not outweigh the potential risks associated with their use and, therefore, should not continue to be extensively marketed. Unigene is the manufacturer of Fortical Nasal Spray, a calcitonin-containing product indicated for the treatment of osteoporosis. In addition, the Advisory Committee recommended that fracture prevention data should be required for the approval of new oral calcitonin products in development for osteoporosis prevention and treatment.
Unigene Laboratories, Inc. (UGNE), closed Friday's session at $0.0999, up 21.83%, on 394,600 volume with 42 trades. The average volume for the last 60 days is 115,777 and the stock's 52-week low/high is $0.025/$0.54.
Westinghouse Solar, Inc. (WEST)
Greenbackers and Penny Stock Rumble reported recently on Westinghouse Solar, Inc. (WEST), Alternative Energy, Street Insider, OTCPicks, PennyTrader Publisher, Investor Ideas reported earlier, and we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Listed on the OTC Markets' OTCQB, Westinghouse Solar, Inc. is a designer and manufacturer of integrated rooftop solar power systems. They design and manufacture solar power systems and solar panels with integrated microinverters (which they call AC solar panels). The design of their products is for use in solar power systems for residential and commercial rooftop customers. Founded in 2001, Westinghouse Solar has their headquarters in Campbell, California.
The Company designs, markets and sells their solar power systems to solar installers, trade workers and do-it-yourself customers in the United States and Canada by way of distribution partnerships, the Company's dealer network, as well as retail outlets. The Company introduced their "plug and play" solar panel technology (going by the brand name Andalay), in September of 2007.
Westinghouse Solar broke new ground in 2009 with the first integrated AC solar panel, reducing the number of components for a rooftop solar installation by approximately 80 percent and lowering labor costs by approximately 50 percent. This AC panel won the 2009 Popular Mechanics Breakthrough Award. It has become the industry's most widely installed AC solar panel. Westinghouse Solar has also introduced a new generation of products named "Instant Connect".
Westinghouse Solar has three U.S. patents (Patent No. 7,406,800, Patent No. 7,832,157 and Patent No. 7,866,098) that cover key aspects of their solar panel technology, as well as U.S. Trademark No. 3481373 for registration of the mark "Andalay." The Company received three foreign patents in 2010: Australian Patent No. 2,005,248,343, Indian Patent No. 243,626, and Mexican Patent No. 274,182. A Korean Patent No. 751,614 was issued in 2007.
Currently, Westinghouse Solar has seven issued patents and eighteen other pending U.S. and foreign patent applications that cover the Andalay technology working their way through the USPTO and foreign patent offices.
The Company has their Westinghouse Solar Authorized Dealer Program. The Westinghouse Solar Dealer Program provides opportunities for installers. They can build their business with a trusted brand name and first-rate technology from the Company. The Company's program provides installers with the rights to use the highly recognizable Westinghouse name and logo; Dealer Financing; sales tools such as collateral, presentations and videos to help them close more deals; sales leads, technical and sales training, and more.
Westinghouse Solar, Inc. (WEST), closed Friday at $0.059, up 5.92%, on 330,871 volume with 32 trades. The average volume for the last 60 days is 616,545 and the stock's 52-week low/high is $0.0335/$0.20.
Arianne Resources, Inc. (DAN.V)
We are highlighting Arianne Resources, Inc. (DAN.V) today, here at the QualityStocks Daily Newsletter.
Arianne Resources, Inc. is a mineral exploration company primarily focused on developing the Lac a Paul phosphorus-titanium project in the Province of Quebec. The world-class phosphorus and titanium deposits of Lac a Paul constitute the leading project of the Company and are among the largest of this type in Canada. Arianne Resources is actively developing this project with construction planned for 2014 and production in 2016. The Company has their corporate headquarters in Chicoutimi, Quebec.
The Lac a Paul project is a proposed open pit mine located approximately 200 km north of the Saguenay-Lac-St-Jean. The expectation is that the phosphate deposits will produce high quality igneous apatite concentrate grading approximately 39 percent P2O5 with little or no contaminant. The project will generate approximately 400 direct and 400 indirect jobs mainly in the Saguenay–Lac-St-Jean region.
Arianne Resources' other projects include James Bay, La Dauversière, El Rey, Heva, and Brouillan-Fénélon. Moreover, the Company has several additional phosphate and titanium properties and rare earth properties.
In January 2013, Arianne Resources announced that they would seek shareholders' approval to change their name to "Arianne Phosphate, Inc." at their next annual general meeting of shareholders in May 2013. This is for recognizing the focus of their activities on developing the world class Lac a Paul phosphate deposit. The name change will also be subject to regulatory approval.
In addition, they announced their intention to divest all non-phosphate exploration properties to focus exclusively on becoming a leading Canadian Phosphate producer. The assets remaining in the Company will exclusively focus on phosphate. The primary assets are the Lac a Paul deposits and some other phosphate exploration properties. The projects they will sell include Heva, La Dauversière, Black Dog, Chico, Dulain, and Terres Rares. The Company expects to complete the divestment process during 2013.
Yesterday, Arianne management announced that the updated mineral estimate for the Paul Zone amounts to 590 million metric tons (Mt) of measured and indicated resources. This National Instrument 43-101-compliant resource calculation conducted by GoldMinds Geoservices, Inc., in cooperation with Arianne personnel, provides an updated estimate of the resources present in the Paul Zone. This zone is the main zone of the Lac a Paul phosphorus mining project.
Arianne Resources, Inc. (DAN.V), closed Friday's trading session at
VistaGen Therapeutics, Inc. (VSTA)
The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTA). Today, VistaGen Therapeutics, Inc. closed trading at $0.90, up 38.40%, on 5,000 volume with 4 trades. The stock’s average daily volume over the past 60 days is 2,966, and its 52-week low/high is $0.06/$2.85.
VistaGen Therapeutics, Inc. (VSTA) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs.
VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.
By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve. According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.
Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months. VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits. In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations.
AV-101, VistaGen's lead small molecule prodrug candidate has successfully completed Phase I clinical development in the U.S. for treatment of neuropathic pain, a serious and chronic condition affecting millions of people worldwide, depression, and other neurological diseases and conditions. To date, the U.S. National Institutes of Health (NIH) has awarded VistaGen over $8.75 million for development of AV-101. Management anticipates strategically out-licensing AV-101 to a development and marketing partner in 2013.
Neuropathic pain affects approximately 1.8 million people in the U.S. alone. Although the current active AV-101 IND is for the treatment of neuropathic pain, VistaGen's development plan and regulatory strategy for AV-101 has been designed to allow its Phase 1 safety studies to support Phase 2 development for depression, epilepsy, Huntington's Disease and Parkinson's disease, indications for which there is now supporting preclinical efficacy data. To date, VistaGen has been awarded over $8.5 million from the U.S. National Institutes of Health (NIH) for development of AV-101.
VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer
VistaGen Therapeutics, Inc. Company Blog
VistaGen Therapeutics, Inc. News:
VistaGen Therapeutics Enters Strategic Collaboration With Celsis to Further Advance LiverSafe 3Dô
VistaGen's Collaborators Identify Definitive Precursor for Adult Blood and the Immune System
Vistagen Therapeutics Successfully Completes Final Phase 1 Safety Study of AV-101
Bergamo Acquisition Corp. (BGMO)
The QualityStocks Daily Newsletter would like to spotlight Bergamo Acquisition Corp. (BGMO). Today, Bergamo Acquisition Corp. closed trading at $0.036, up 20.40%, on 173,000 volume with 10 trades. The stock’s average daily volume over the past 60 days is 171,908, and its 52-week low/high is $0.01/$0.065.
Bergamo Acquisition Corp. (BGMO) is a global investor targeting a diversified portfolio of large corporate and middle-market companies for sole acquisition and co-investment alongside other sophisticated investors such as private equity funds, hedge funds, investment banks, and other institutions. The company has engaged investments in financial instruments and companies worldwide.
Alternative energy is a key focus of the company. Bergamo Acquisition has developed solar generators for cell phone towers, solar generators for home and industry applications, and solar operated tube well water pumping systems to meet the vast needs of emerging markets. The company’s turnkey solutions help developers, utilities, water districts, power plant owners, and industrial customers diversify their existing generation portfolio.
Bergamo Acquisition executes energy projects from concept through completion, offering design, construction management, and facility maintenance services. Together with pre-designed and packaged Balance of Plant and standardized Power Plant Control Modules, the company enables rapid project commissioning and provides an optimum balance between capital cost, plant performance, and operational and maintenance expenses.
The company’s technical team has been working with government officials, manufactures, and importers in Asia, Africa, and the Middle East to introduce its state-of-the-art technology. Investable funds are already in place to pursue investment opportunities in these and other countries. Bergamo Acquisition relies on its extensive network within the global institutional investment and banking industries to source the best opportunities. Disclaimer
Bergamo Acquisition Corp. Company Blog
Bergamo Acquisition Corp. News:
Bergamo Acquisition Corp. Provides Authenticated Documentation to Confirm Bank Deposits
L.L. Bradford Letter Confirms Funding Reported by Bergamo Acquisition Corp.
Bergamo Acquisition Corp. Signs Investment Agreement
HII Technologies, Inc. (HIIT)
The QualityStocks Daily Newsletter would like to spotlight HII Technologies, Inc. (HIIT). Today, HII Technologies, Inc. closed trading at $0.14, up 3.70%, on 61,930 volume with 7 trades. The stock’s average daily volume over the past 60 days is 83,463, and its 52-week low/high is $0.015/$0.22.
HII Technologies, Inc. (HIIT) is an oilfield services company serving the power, water, and safety markets with innovated solutions that are in high demand and used by exploration and production (E&P) companies. With over a decade of experience in the energy business, the company has established a solid track record as well as developed an extensive network of relationships with oil and gas E&P companies, energy consultants and advisors, vendors, suppliers, and strategic corporate partners.
HII Technologies' power subsidiary, South Texas Power, provides portably onsite diesel and natural gas generators to E&P companies that are in remote areas and don't have ready access to a power grid. AES Water Solutions, the company's water transfer division, provides above ground temporary infrastructure to transfer millions of gallons of water needed in connection with hydro-fracing of oil and gas wells. HII Technologies' safety consulting business, AES Safety Services, helps E&P companies meet the increasing state and federal requirements for 24/7 safety personnel on site from the early stages of preparing for drilling to the final completion work.
Management's relationships in the markets it operates is a key to the company's success. Matt Flemming, CEO of HII Technologies has twenty years' experience as CFO and CEO of high growth companies and ten years in oil and gas services and manufacturing markets. Brent Mulliniks, P.E., is a frac engineer by training and as President of AES Water Solutions brings significant experience and knowledge to the hydro-fracing water transfer business. Jason Cuevas, GM of South Texas Power, was previously GM of National Oilwell Varco Portable Power division in the heart of the Eagle Ford Shale in S. Texas.
The company seeks differentiation of its operating divisions by accessing and acquiring technologies, as well as evaluating joint ventures, while successfully executing its organic growth strategy. Significant growth and profitability is projected by management as the company continues to meet the needs of the ever expanding energy marketplace. Leveraging an array of competitive strengths and deep expertise in the energy services business, HII Technologies is well positioned as one of the most dynamic oilfield service companies in the United States. Disclaimer
HII Technologies, Inc. Company Blog
HII Technologies, Inc. News:
HII Technologies, Inc. Announces Engagement of QualityStocks Investor Relations Services
HII Technologies, Inc. Announces New Safety Services business unit
HII Technologies, Inc. Announces Preliminary 4th Quarter 2012 Results
International Stem Cell Corp. (ISCO)
The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $0.281, up 0.36%, on 77,905 volume with 33 trades. The stock’s average daily volume over the past 60 days is 195,008, and its 52-week low/high is $0.161/$0.65.
International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. The company was first to perfect the natural phenomenon of parthenogenesis, which utilizes unfertilized human eggs to create hpSCs. These stem cells, created in a particular form called HLA homozygous, can be immune-matched to millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.
hpSCs are as pluripotent as embryonic stem cells (ESCs) and have significant therapeutic potential but their creation does not involve the destruction of a viable human embryo – thus sidestepping the controversy and ethical dilemmas associated with the use of human embryonic stem cells. Different from induced pluripotent stem cells (iPSs), hpSCs do not involve manipulation of gene expression back to a less differentiated stage – a practice that may become a safety or regulatory obstacle in clinical applications.
A relatively small number of hpSC lines can offer the potential of producing the first true stem cell bank, UniStemCell, which ISCO intends to create as a means of serving populations across the globe. The company's scientists are currently focused on using hpSC to treat severe diseases of the eye, nervous system, and liver, for which cell therapy has been clinically proven but is limited due to the unavailability of safe human cells.
In addition to its therapeutic focus, ISCO also provides two revenue streams. Firstly through its subsidiary Lifeline Cell Technology, specialized cells and growth media for biological research around the world, and secondly its subsidiary Lifeline Skin Care, the company manufactures and sells anti-aging skincare products utilizing an extract from the hpSC and by leveraging the latest discoveries in the fields of stem cell biology, nanotechnology, and skin cream formulation technology. Disclaimer
International Stem Cell Corp. Company Blog
International Stem Cell Corp. News:
International Stem Cell Corporation to Present at 65th American Academy of Neurology Annual Meeting
International Stem Cell Corporation Strengthens Intellectual Property Portfolio
International Stem Cell Corporation Demonstrates Positive Animal Efficacy Results in Metabolic Liver Disease Program
International holding company Bergamo Acquisition and its subsidiaries are actively creating a diversified portfolio of varying-size companies using strategic one-off investments, together with acquisitions and co-investments. The company is working with significant institutional investors, such as private equity funds, hedge funds, investment banks, and related institutions, and is targeting, among others, alternative energy, biotechnology, and healthcare markets.
Utilizing a unique set of well-established high-level financial connections, Bergamo has developed a distinctive process of co-investments that provides it a significant flow of funds for the separate and independent financing of acquisitions. In May 2012, the company purchased 100% of the stock in a European entity via its wholly owned subsidiary in Singapore to implement its investment strategies using both European currency and U.S. dollars. The company leverages its broad network within the global institutional investment and banking industries to identify potential opportunities.
Key to the development and implementation of this strategy is Bergamo’s globally-experienced management team.
• Hillard Herzog, President of Bergamo Acquisition and its global subsidiaries, has founded and served as president of several companies in the apparel manufacturing and retail industry, including Clothing Source of California and Jayre of California, Inc. Mr. Herzog has further held executive positions with several other publicly traded apparel and accessories manufacturers and retailers, including Van Raalte Company, Inc. (NYSE), Cluett Peabody (NYSE), and N.C.C. Industries (AMEX). Mr. Herzog has a Juris Doctorate from Brooklyn Law School.
• Sohail Parekh, Sr. Executive VP and Director, is a third generation clothing executive, and a co-founder of Clothing Source of California, where he served as Executive Vice President and Chief Financial Officer from inception through to their acquisition in 2002 by Bergamo Acquisition. Sohail brings to Bergamo Acquisition a highly connected relationship with the developing countries.
• Ayaz Lakhani, CEO of Bergamo Global Energy Private Ltd., is Chairman and CEO of Haanz Group. Mr. Ayaz Lakhani has built a successful career in the field of diverse businesses worldwide, including alternative energy, mining, hospitality, health and wellness, food and beverage, and manufacturing.
For additional information, visit www.BergamoCorp.com
Nothing is more dangerous to a diabetic than developing skin or tissue ulcers which may, if left untreated, necessitate the amputation of a finger, a toe, or even an entire hand or foot.
These ulcers, the result of advanced diabetes or certain neuropathic conditions – in which wounds were left untreated – appear as a result of slowed circulation to extremities, a condition associated with both types of diabetes (i.e., Type I, an auto-immune disease, and Type II, which exhibits as high levels of sugar in the blood).
These ulcers result in almost 80,000 lower extremity amputations yearly in the U.S., most often among elderly diabetics who have already lost some degree of mobility. It is this cohort – the 55 to 64-year old group, and those over 85 – which Cardium’s Excellagen aims to address with an eye to lowering the odds of amputation and raising the likelihood of cures.
Excellagen, cleared by the U.S. Food and Drug Administration, or FDA, and packaged in individual syringes for doctors’ ease of use, provides a collagen that acts as a noncellular biological modulator. This compound, which contains no cells and resembles a cytoplasm, is in fact a collagen gel – a naturally-produced substance derived from the skin, muscle, bones, and tendons of cattle or ruminants.
In the hospital or clinic, Cardium’s 2.6 percent (of total volume) collagen gel behaves as a stimulant to speed up the formation of granulation tissue in and around the wound for more rapid and greatly improved ulcer healing.
Whether used for diabetic foot ulcers, pressure ulcers, venous ulcers, or surgical and other type wounds, Excellagen excels when professionally administered after standard debridement technologies, which aim to scrape away dead tissue to encourage the formation of blood cells and platelets essential to the release of endogenous growth factors. These factors have been shown elsewhere to support and extend the migration of surviving cells in vitro – a highly beneficial feature that Cardium’s researchers incorporated into their high molecular weight fiber-based Type I bovine collagen gel (BCG).
Administering Excellagen once per week, in the presence of blood cells and platelets which naturally encourage the production and deposition of platelet-derived growth factor, or PDGF, has proven to be superior wound-healing technology. In fact, Excellagen trials across a spectrum of skin and tissue injuries, and ulcers, have shown Cardium’s product superior to some other wound care approaches, largely because Excellagen is capable of speeding up granular tissue growth.
Cardium’s product also shows exceptional promise in the dermatology marketplace, where its ability to stimulate skin repair in the aftermath of surgery for patients suffering from squamous and basal cell carcinomas (two forms of skin cancer) has been highly rewarding. Similar therapy has also resulted in tissue repair deep into the periosteum, a membrane that covers bones. Finally, research into directing endochondral bone formation after implantation, which requires a biocompatible material as a scaffold to support growth, may see Excellagen or similar compounds being used to heal bony material.
In time, Cardium’s Excellagen could even find use as a collagen-based formula for the topical administration of antibiotics, peptides, proteins, DNA, stem cells, molecules, and the like. Given its healing ability – a 173-percent increase over other standard-of-care therapies in a single week – expect to see Excellagen appearing in many yet-to-be-determined venues.
For more information, visit www.CardiumTHX.com
Mimvi, the pure-play mobile tech company which grew out of Kasian Franks’R&D 100 award-winning search engine technology that uses biomimetics and is therefore capable of delivering highly-personalized, relevant results, reported today that the company has inked a major agreement with LA-based media firm and host to a whole slew of consumer-branded websites and businesses,Webxu, Inc., who will now implement MIMV’s Search and Recommendation API.
The giant network of sites (including DegreeBuilder.com and CarsBlvd.com) which Webxu maintains is a perfect fit for MIMV’s technology. The MIMV API will allow Webxu to efficiently monetize traffic via search tools across the entire landscape of proprietary and partner properties in their network. This network represents a huge volume of traffic, well over 10M pages views a month all told, and because the core MIMV technology can be distributed and easily used in so many different ways, publishers will be able to rapidly implement a free search and discovery functionality for their visitors.
Mimvi’s extremely portable technology can be injected in a variety of ways and the recent deployment of their search bar inside a handy widget offers publishers a super easy way to just drop in the plugin and instantly offer users powerful search intelligence. Moreover, the Mimvi open API gives developers the tools they need to make new and even more awesome apps built on the core tech, MIMV even provides full documentation on the API for interested developers. This is a huge boon, as anyone who has developed software will immediately realize and MIMV is giving publishers/developers all the tools they need to significantly improve user experience, whether we are talking search tools or ad relevance.
CEO of MIMV, Michael Poutre, characterized the deal with Webxu as a huge springboard for both companies and assured shareholders that this is precisely the kind of company MIMV should be working with, especially considering the huge traffic pipe already created by Webxu, which looks like the quintessential deployment space for this kind of technology. To put it succinctly, Poutre explained that apps are like the gateway to the entire mobile space and MIMV’s API is the key to unlocking that gateway, here also enabling Webxu to achieve new monetization highs while providing users with powerful new features.
CEO of Webxu, Keith Schaefer, asseverated wholeheartedly, adding that the goal over at Webxu is to provide users with only the most relevant advertising, while maintaining a consistently high quality level for user experiences across the entire proprietary and partner landscape. MIMV’s technology helps accomplish this task easily and locks down a future development vector as well, all in one fell swoop. The kinds of mobile tools and additional online features that can be created from the proprietary search and intelligent recommendation algorithm backbone MIMV provides are virtually limitless.
MIMV makes it really easy to discover great mobile apps and content, as well as mobile products across the entire spectrum of hardware devices and platforms, from Apple and Android, to BlackBerry and Windows Phone, even endpoints like Facebook and the broader web applications space are made easily accessible by this ingenious technology. Really nice to see MIMV and Webxu hooking up like this and investors will want to keep an eye on the relationship as time advances for prevailing downstream innovations that will likely occur as a result of this marriage of network and intelligent search/recommendation technology.
For more information on Mimvi, visit corp.Mimvi.com
FalconStor Software, a market leader in disk-based data protection, announced that one of its founders and current board member, Barry Rubenstein, has been awarded The Long Island Technology Hall of Fame Entrepreneur Award for his efforts in building Long Island as a technology business hub. In addition to the award, Rubenstein, along with other Long Island science and technology business leaders, was inducted into The Long Island Technology Hall of Fame (LITHF) during the award ceremony earlier this week. By serving as an advisor to, investing in, and founding several local technology companies, Rubenstein has made significant contributions to Long Island’s business community.
Now in its 12th year, LITHF has a long-standing tradition of honoring contributions of science and technology business leaders who have had or are having an impact on the region’s economic development and commitment to the community. Individuals are selected by the awards committee according to intellectual acumen, lifetime achievement, overall impact on the advancement of science and technology, and national prominence.
“In awarding Long Island Technology Hall of Fame’s Entrepreneur Award to Barry Rubenstein, the organization recognizes his exceptional talent and capabilities as an entrepreneur who will continue to benefit Long Island, now and in the future, as we position our region as a leading technology hub,” commented Adam Silvers, partner at Ruskin Moscou Faltischek and member of the Long Island Technology Hall of Fame Selection Committee.
A general partner at Wheatley Partners, Rubenstein has a long history of investing in and founding technology companies, starting in 1969, signifying his commitment to building the Long Island business technology community. Rubenstein has been a founding consultant in several firms, including Applied Digital Systems, Inc.; FatWire Software; Novell, Inc.; Cheyenne Software, Inc.; Scan Source; and FalconStor Software. As a founder, past chairman and current board member of FalconStor, Rubenstein has contributed extensively to the establishment of the company’s leadership in the data protection industry. He has continuously provided ongoing support for the Long Island technology community by serving as a valued advisor and board member for several different firms.
For more information on FalconStore Software, visit www.falconstor.com
Today's Top 3
Wall Street Resources
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- Advaxis, Inc. (ADXS) to Provide 2013 Business Outlook on March 6, 2013
- Bergamo Acquisition Corp. (BGMO) Provides Authenticated Documentation to Confirm Bank Deposits
- Consorteum Holdings, Inc. (CSRH) Reaches Funding Agreement With Private Equity Group
- Cardium Therapeutics, Inc. (CXM) Announces Presentation at The 2013 Cell & Gene Therapy Forum
- Duma Energy Corp. (DUMA) Receives 1.1 Billion Barrel P10 Estimate for Namibia Concession
- GlobalWise Investments, Inc. (GWIV) CEO to Speak at Technology United Executive Conference
- HII Technologies, Inc. (HIIT) Announces Engagement of QualityStocks Investor Relations Services
- International Stem Cell Corp. (ISCO) Strengthens Intellectual Property Portfolio
- Loans4Less.com, Inc. (LFLS) Engages CPA Firm to Audit Financials
- Rafarma Pharmaceuticals, Inc. (RAFA) Receives General License for Pharmaceutical Products Starts Mfg. 3 New Products
- Rainbow Coral Corp. (RBCC) Opens Talks to Help Develop Revolutionary Breakthrough in $60 Billion Drug Delivery Market
- The Guitammer Company Inc. (GTMM) Joins Nationwide, North America's Largest Buying and Marketing Organization
- Viaspace, Inc. (VSPC) 25 Acres of Giant King Grass Shipped and Growing in St. Croix
- Viscount Systems, Inc. (VSYS) Freedom Installed at Additional BC Government Sites
- VistaGen Therapeutics, Inc. (VSTA) Becomes Member of Centre for Commercialization of Regenerative Medicine Consortium